Research location

Nitra

Slovakia, Slovakia

Published trials7
Site observations8
Linked trials published7
Page1 / 1
Advertisement

Research activity in Nitra

Slovakia, Slovakia

CureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 8 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Nitra

7 linked trials · page 1 of 1
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart FailureNCT06142383 · 2023-12-12 · 1 site observation
TERMINATED
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabNCT04353492 · 2020-07-14 · 1 site observation
COMPLETED
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionNCT01281306 · 2011-01-01 · 2 site observations
COMPLETED
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailureNCT01035255 · 2009-12-01 · 1 site observation
TERMINATED
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart FailureNCT00894387 · 2009-05-01 · 1 site observation
COMPLETED
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)NCT00549757 · 2007-10-01 · 1 site observation
TERMINATED
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic PatientsNCT00391196 · 2006-11-01 · 1 site observation
TERMINATED

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.